RT Journal Article
SR Electronic
T1 Biallelic pathogenic variants in TRMT1 disrupt tRNA modification and induce a syndromic neurodevelopmental disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.18.24310581
DO 10.1101/2024.07.18.24310581
A1 Efthymiou, Stephanie
A1 Leo, Cailyn P
A1 Deng, Chenghong
A1 Zhang, Kejia
A1 Lin, Sheng-Jia
A1 Maroofian, Reza
A1 Kaiyrzhanov, Rauan
A1 Lin, Renee
A1 Karagoz, Irem
A1 Scardamaglia, Annarita
A1 Owrang, Daniel
A1 Turchetti, Valentina
A1 Jahnke, Friederike
A1 Petree, Cassidy
A1 Derrick, Anna V
A1 Rees, Mark I
A1 Alvi, Javeria Raza
A1 Sultan, Tipu
A1 Li, Chumei
A1 Jacquemont, Marie-Line
A1 Tran-Mau-Them, Frederic
A1 Valenzuela-Palafoll, Maria
A1 Sidlow, Rich
A1 Yoon, Grace
A1 Morrow, Michelle
A1 Carere, Alexis
A1 O’Connor, Mary
A1 Fleischer, Julie
A1 Gerkes, Erica H
A1 Phornphutkul, Chanika
A1 Isidor, Bertrand
A1 Rivier-Ringenbach, Clotilde
A1 Philippe, Christophe
A1 Kurul, Semra H
A1 Soydemir, Didem
A1 Kara, Bulent
A1 Sunnetci-Akkoyunlu, Deniz
A1 Bothe, Viktoria
A1 Platzer, Konrad
A1 Wieczorek, Dagmar
A1 Koch-Hogrebe, Margarete
A1 Rahner, Nils
A1 Thuresson, Ann-Charlotte
A1 Matsson, Hans
A1 Frykholm, Carina
A1 Bozdoğan, Sevcan Tuğ
A1 Bişgin, Atıl
A1 Chatron, Nicolas
A1 Lesca, Gaetan
A1 Cabet, Sara
A1 Tümer, Zeynep
A1 Hjortshøj, Tina D
A1 Rønde, Gitte
A1 Marquardt, Thorsten
A1 Reunert, Janine
A1 Afzal, Erum
A1 Zamani, Mina
A1 Azizimalamiri, Reza
A1 Galehdari, Hamid
A1 Nourbakhshd, Pardis
A1 Chamanrou, Niloofar
A1 Chung, Seo-Kyung
A1 Suri, Mohnish
A1 Benke, Paul J
A1 Zaki, Maha S
A1 Gleeson, Joseph G
A1 Calame, Daniel G
A1 Pehlivan, Davut
A1 Yilmaz, Halil I
A1 Gezdirici, Alper
A1 Rad, Aboulfazl
A1 Abumansour, Iman Sabri
A1 Oprea, Gabriela
A1 Sidpra, Jai
A1 Mankad, Kshitij
A1 Vona, Barbara
A1 Fry, Andrew E
A1 Varshney, Gaurav K
A1 Houlden, Henry
A1 Fu, Dragony
YR 2024
UL http://medrxiv.org/content/early/2024/07/22/2024.07.18.24310581.abstract
AB The post-transcriptional modification of tRNAs plays a key role in tRNA folding and function to ensure proper levels of protein synthesis during growth and development. Pathogenic variants in tRNA modification enzymes have been implicated in diverse human neurodevelopmental and neurological disorders. However, the molecular basis for many of these disorders remains unknown, thereby limiting our understanding and potential treatment of pathologies linked to tRNA modification. Here, we describe an extensive cohort of 31 individuals from 24 unrelated families with bi-allelic variants in the tRNA methyltransferase 1 (TRMT1) gene who present with a syndromic neurodevelopmental disorder universally characterized by intellectual disability in affected patients. Developmental delay, behavioral abnormalities and facial dysmorphisms represent additional core phenotypes of this syndrome. The variants include novel and ultra-rare TRMT1 variants that segregate with clinical pathology. We found that a subset of variants causes mis-splicing and loss of TRMT1 protein expression. Notably, patient cells with TRMT1 variants exhibit a deficiency in tRNA modifications catalyzed by TRMT1. Molecular analysis of TRMT1 variants reveal distinct regions of the TRMT1 protein required for tRNA modification activity and binding, including a TRMT1 subdomain critical for tRNA interaction. Importantly, depletion of TRMT1 in zebrafish is sufficient to induce developmental and behavioral phenotypes that recapitulate those observed in human patients with pathogenic TRMT1 variants. Altogether, these findings demonstrate that loss of TRMT1-catalyzed tRNA modifications leads to a syndromic form of intellectual disability and elucidate the molecular underpinnings of tRNA modification deficiency caused by pathogenic TRMT1 variants.Competing Interest StatementM.M.M and A.C are employees of GeneDx, LLC. R.S. is on the advisory board for Guide Genetics and Egetis Pharmaceuticals.Funding StatementThe research in this manuscript was supported by NIH GR530882 to D.F. Studies performed in the lab of G.K.V was funded by NIH R24OD034438. The clinic-genetic research was funded in part, by the Wellcome Trust (WT093205MA, WT104033AIA). This study was funded by the Medical Research Council (MR/S01165X/1, MR/S005021/1, G0601943), The National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetrees Trust, Ataxia UK, Multiple System Atrophy Trust, Brain Research United Kingdom, Sparks Great Ormond Street Hospital Charity, Muscular Dystrophy United Kingdom (MDUK), Muscular Dystrophy Association (MDA USA) and the King Baudouin Foundation. SE and HH were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1. B.V. was supported by the Deutsche Forschungsgemeinschaft (DFG) DFG VO 2138/7‐1 grant 469177153. J.S. is supported by Cancer Research UK and University College London. A.F. and S.C. are supported by Health & Care Research Wales, Epilepsy Research UK, PhD Swansea University funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The accredited Medical Ethics Review Committee of the University College London Hospital, as well as all collaborating local institutional IRBs have approved the collection of biomaterial samples and clinical information as well as functional analysis of human DNA and fibroblasts. The patients and their families provided informed consent for participation in the study and publication of the results.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that supports the findings of this study are available within the paper and in the supplementary material. Whole-exome sequencing data are not publicly available due to privacy or ethical restrictions. The novel TRMT1 variants reported in this manuscript were submitted to the LOVD database (https://databases.lovd.nl/shared/genes/TRMT1), with the LOVD variant IDs: # 0000944528, # 0000944622, # 0000944624, # 0000944625, # 0000944626, # 0000944640, # 0000944641, # 0000944642, # 0000944643, # 0000944646, # 0000944620, # 0000944621, # 0000944647, # 0000944709, # 0000944708, # 0000944710, # 0000944712, # 0000944713, # 0000944714, # 0000944715, # 0000944716, #0000959740, #0000959741, #0000959742, #0000959743.